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Summary
Mild hyperhomocysteinemia is an established risk factor 
for cardiovascular disease. Genetic aberrations in the
Introduction
Over the past decade, mild hyperhomocysteinemia has
cystathionine (3-synthase (CBS) and methylenetetrahy- been recognized as a risk factor for occlusive arterial 
drofolate reductase (MTHFR) genes may account for disease and thiomxxsis (Wi cken and Wi cken 1976; 
reduced enzyme activities and elevated plasma homocys- Boeis et al. '19856; Kang et a . ; Malinow 1994;
teine levels. In 15 unrelated Dutch patients with homo­
zygous CBS deficiency, we observed the 833T-»C  
(I278T) mutation in 50% of the alleles. Very recently.
Den Heijer et al. 1995), Homocysteine levels are influ­
enced by environmental (folate, vitamin B6, and vitamin 
B12 intake) as well as genetic factors (Boers et al. 19856;
we identified a common mutation (677C-+T; A“>V) in Kang et al. 1992; Millei et al. 1992; Daly et al. 1993; 
the MTHFR gene, which, in homozygous state, is re- Selhub et al. 1993; Guttormsen et al, 1994).
sponsible for the thermolabile phenotype and which is Classic homocystinuria, which is inherited as an au-
associated with decreased specific MTHFR activity and tosomal recessive tiait, is charactei ized by severely ele-
elevated homocysteine levels. We screened 60 cardiovas*- vated concentrations ol homocysteine and methionine
in blood and urine and is caused by a genetic deficiency
of cystathionine (3-syntliase (CBS) (Finkelscein et al, 
1964). In the transsulfuration pathway, CBS catalyzes 
the condensation of homocysteine and serine to cystathi­
onine. Life-threatening complications of CBS deficiency
in patients with premature cardiovascular disease. Ho- are Premature arteriosclerosis and thrombosis (Boers
cular patients and 1 1 1  controls for these two mutations, 
to determine whether these mutations are risk factors 
for premature cardiovascular disease. Heterozygosity 
for the 833T~»C mutation in the CBS gene was observed 
in one individual of the control group but was absent
mozygosity for the 6 7 7 G ^T mutation in the MTHFR 1986). To date, 17 mutations have been found in the
gene was found in 9 (15%) of 60 cardiovascular patients CBS gene in homozygous CBS-deficient patients (Kraus
and in only 6 (~5% ) of 1 1 1  control individuals (odds 1994; Kluijtmans et al, 1995). Reduced activities in the
ratio 3 .1  [95% confidence interval 1 .0-9.21). Because range of obligate heterozygotes for CBS deficiency have
of both the high prevalence of the 833T~>C mutation 
among homozygotes for CBS deficiency and its absence
been reported in vascular patients with mild hyperho­
mocysteinemia (Boers et al. 19856; Clarke et al. 1991),
in 60 cardiovascular patients, we may conclude that suggesting a causal role for heterozygosity for CBS defi-
heterozygosity for CBS deficiency does not appear to be ciency in premature vascular disease. However, Mudd
involved in premature cardiovascular disease. However, et al. (198 U reported a normal incidence of heart attacks
or strokes in a large group of obligate heterozygotes fora frequent homozygous mutation in the MTHFR gene is 
associated with a threefold increase in risk for premature 
cardiovascular disease.
»  ♦
Received July 13, 1995; accepted for publication September 22,
1995.
Address for correspondence and reprints: Dr. Henk J. Blom, D epart­
ment of Pediatrics, University Hospital Nijmegen, P.O. Box 9101, 
6500 HB Nijmegen, The Netherlands.
© 1996 by The American Society of Human Genetics, All rights reserved. 
0002-9297/96/5801-0006$02>00
CBS
A less frequent form of severe hyperhomocysteinemia 
is methylenetetrahydrofolate reductase (MTHFR) defi­
ciency. MTHFR is a regulating enzyme in folate-depen- 
dent homocysteine remethylation; it catalyzes the re­
duction of 5 ,1 0-m ethylenetetrahydrofolate to 5- 
m e t h y 11 e t r a h y d r o f o 1 a t e . C o m p a r e d with c o n t r o 1 s, 
patients with severe hyperhomocysteinemia due to 
MTHFR deficiency show virtually no residual MTHFR 
activity in isolated lymphocytes and also have an in-
35
36 Am. J. Hum. Genet, 5S:35-4l> 1996
creased risk of arteriosclerosis and thrombosis (Rosen- had suffered from myocardial infarction, 32 from cere-
blatt 1989).
In 1988, a thermolabile variant of the MTHFR en-
bral arterial occlusive disease, and 18 from peripheral 
arterial occlusive disease. Cardiovascular disease had
zyme was described with a specific M THFR activity been diagnosed in these patients by use of standard 
< 5 0 %  of the control value in lymphocytes and with methods and techniques as reported by us elsewhere
(Boers et al. 19856). Excluded from this study were 
patients with the following known risk factors for vascu­
lar disease: hyperlipoproteinemia (fasting serum levels 
of cholesterol > 6 .5  mmol/liter and triglycerides >2.0
decreased thermostability after inactivation at 46°C 
(Kang et al. 1 9 8 8 ^  19886). On the basis of the biochem­
ical phenotype evaluation of subjects with thermolabile 
M TH FR  and of their family members, Kang et al. (1991)
concluded that thermolability of MTHFR is inherited mmol/liter), hypertension (systolic and diastolic blood
as an autosomal recessive trait. They reported a fre- pressure > 150  and > 9 0  mmPIg, respectively), and dia-
quency of this thermolabile M THFR enzyme of 17% in betes mellitus (fasting plasma glucose levels >5.6 mmol/
coronary artery disease and of 5 % in controls. In an- liter). No other exclusion criteria were employed. The
other study, the same group demonstrated a positive study group did not consist of patients reported by us
association between the severity of coronary artery ste- elsewhere (Engbersen et al. 1995). Five patients had re-
nosis and the presence of thermolabile MTHFR (Kang duced vitamin 1312 concentrations (<150  pmol/liter),
et ah 1993). This association was independent of other and two patients were folate deficient (<5.0  nmol/liter).
known risk factors for coronary artery disease. In a pre- Control subjects (n = 111; age 2 3 -7 5  years) were
vious study from our group, on patients with cardiovas- recruited from a general practice in The Hague (Den 
cular disease, we observed an incidence of a thermolabile Heijer et al. 1995). All subjects agreed to participate in 
M THFR enzyme in 11 (—28%) of 39 hyperhomocys- this study,
teinemic cardiovascular patients and in '1 (~5% ) of 23 Fifteen unrelated patients with homocystinuria due to
controls (Engbersen et al. 1995). All these studies indi- CBS deficiency were studied for the 833T->C transition, 
cate that thermolabile MTHFR may be a significant risk The diagnosis was established by severe hyperhomocys-* 
factor for hyperhomocysteinemia-related cardiovascular 
disease.
teinemia, hypermethioninemia, and decreased levels of 
cysteine in plasma. In addition, CBS activities in cultured
In an earlier work, we reported the isolation of the fibroblasts were < 1 %  of the control mean. Most pa-
human cDNA for MTHFR and the assignment of the tients showed responsiveness to pyridoxine in vivo. The
gene to chromosome lp36.3 (Goyette et al. 1994). Ge- study protocol had been approved by the hospital ethics
netic analysis in severe M THFR deficiency revealed nine committee, 
mutations (Goyette et al. 1994,1995). Very recently, we 
observed a common 677C->T transition in the MTHFR-
coding sequence, which changed a highly conserved ala­
nine into a valine residue; this mutation introduced a
Biochemical Analysis
Cardiovascular patients (n = 60) and controls (;/ 
= 111) were subjected to an oral methionine-loading
HmFI restriction site. Individuals who are homozygous test (0.1 g L-methionine/kg body wt) as described by
for the mutation showed reduced specific MTHFR activ- Boers et al, (19856). Total homocysteine concentrations
ity, increased thermolability, and elevated homocysteine (fasting and post methionine loading) were measured in
concentrations (Frosst et al. 1995), Escherichia colt ex- EDTA plasma by high-performance liquid chromatogra-
pression studies with a mutagenized MTHFR cDNA phy (HPLC) and fluorescence detection (Te Poele-Pot-
demonstrated that this mutation is responsible for the hoff et al. 1995).
thermolabile phenotype (Frosst et al. 1995). CBS activity was measured as described elsewhere
In the present study, we assessed whether the 833T~>C (Fowler et al. 1978; Boers et al. 1985a) and is expressed
transition in the CBS gene, observed in 50% of the al- as nanomoles of cystathionine formed per milligram
leles in Dutch homozygous CBS-deficient patients, was protein per hour. Assays were performed without the
implicated in premature cardiovascular disease. Further- addition of pyridoxal 5'-phosphate to the incubation
more, we examined the prevalence of the homozygous mixture.
677c_> t mutation in the M THFR gene in patients with 
premature cardiovascular disease and in controls. Fi­
nally, we related genotype to biochemical phenotype at 




Specific and residual MTHFR activities in isolated 
lymphocytes were determined radiochemically as de­
scribed extensively by Engbersen et al. (1995). Activities 
are expressed as nanomoles of formaldehyde formed per 
milligram protein per hour. Protein concentrations in 
fibroblast and lymphocyte extracts were determined as 
described by Lowry et al. (1.951). Folic acid and vitamin
We studied 60 patients (age 13 -68  years) with docu- B12 concentrations were determined in heparinized 
mented premature cardiovascular disease, Ten patients plasma, and vitamin B6 concentrations were determined
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in whole blood, all by routine hospital assays (Steegers- controls. The mean homocysteine concentrations (fast-
Theunissen et al. 1994). 
M utation Analysis
ing and post methionine loading) were higher in vascular 
patients than in controls (table 1). The 90th percentile 
of the fasting homocysteine concentration in the control
D NA  was extracted from peripheral lymphocytes as group was 17,1 ¡.imol/liter. In the patient group, 13 
described elsewhere (Miller et al. 1988), and ~ 1 0 0  ng (22,4%) of 58 individuals exceeded this concentration,
was used for PCR amplification. The PCR mixture for versus 11 individuals (10%, by definition) in the control 
analysis of the 833T~>C transition in the CBS gene con­
sisted of 100 ng of the forward oligonucleotide (5'~
GAAGCTGGACATGCTGGTGGC-3'; cDNA position 
7 3 8 -7 5 8 ;  Kraus et ah '1993), 1.00 n g o f  the reverse oligo­
nucleotide (5'-CGCACAGCAGCCCCTCTTG-3f; cDNA 
position 1039-1021),  200 |iM  cINTPs, 10 m M  Tris-
group. The calculated crude odds ratio for fasting homo­
cysteine concentrations >17.1  pmol/Iiter was 2,9 (95% 
Cl '1.1-6'.3). The 90th percentile of the post-methionine- 
loading homocysteine concentration in the control
group was 56.5 (imol/liter. In the patient group, 12 
(20.7%) of 58 exceeded this cutof f point, versus 10 indi-
HCI (piI 8.3), 50 m M  KCl, 1.5 111M  M gC^, 100 )ig viciuals (10%) in the control group, which resulted in a
gelatine/ml, 1 mg Triton X-100/ml, and 1 U T aq  poly- cruc|e 0 dds ratio of 2.6  (95% Cl 1.1-6.5). After adjust-
merase (Life Technologies), in a total volume of 100 ments for age and gender, we found odds ratios of 5.7
pi. The cycle parameters were as follows: 5 min initial (9 5 % Q  1 ,8-17 .4) and 4.0 (9 5 % Cl 1.4-11.6] for
dénaturation atJ?6°C, followed by 35 cycles of '1 min at the fasting and post-methionine-loading homocysteine
concentrations, respectively.
To evaluate heterozygosity for CBS deficiency in car-
93°C, 1 min at 59°C and 2 min at 72°C. Final extension 
was performed at 72°C for 10 min. The 833T-*C m uta­
tion introduces a BsrI restriction site, so the PCR prod- diovascular disease, we first investigated the prevalence 
uct was subjected to BsrI restriction enzyme (New En­
gland Biolabs) analysis, after which the digestion
of the 833T-»C transition in 15 Dutch homozygous
CBS-deficient patients* This 833T-K3 transition ac- 
fragments were resolved in a 6 %  polyacrylamide gel counted for 50%  of the Dutch homocystinuric alleles.
Next, we screened cardiovascular patients and controls 
for the same mutation. We failed to detect the 833T->C 
transition in the patient group (n = 60), whereas 1 het­
erozygote for this mutation was observed among the 
1 1 1 control subjects,
In cardiovascular patients and in controls, we mea­
sured specific M THFR activities in isolated lympho­
cytes, as well as the residual M THFR activity after heat 
inactivation, as a percentage of the specific MTHFR 
activity. The observed mean specific MTHFR activity
containing 5%  glycerol.
For detection of the 677C->T transition in the 
M T H FR  gene, PCR was performed by use of '100 ng 
forward and reverse primer (Frosst et aL 1995) in the 
same buffer as described above. An initial dénaturation 
step was carried out for 5 min at 96°C, followed by 35 
cycles of dénaturation for 50 s at 93°C, primer annealing 
for 50 s at 55°C, and primer extension for 30 s at 72°C. 
A final extension step was performed for 7 min at 72°C. 
HwFI restriction enzyme (Life Technologies) analysis
and subsequent electrophoresis in a 3% agarose gel re- tended to be lower in cardiovascular patients versus con-
vealed the mutational status of the subject. 
Statistics
trois (17.5 ±  7/1, vs. 19.1 ± 6.8 nmol CH^O/mg protein/ 
h; MD 1.6 [95% CI -0 .9 -4 .1 J ) .  The residual MTHFR
activity after heat inactivation showed a significant dif-
Result's arc expressed as the mean ±  SD We « le u - ference between patients and C0 lltf0 ls (53.3% ± 15.7%
l a led mean differences (MD) and 95% confidence inter­
vals (95% CM) for homocysteine concentrations, specific 
M TH FR  activity, and residual MTHlvR activity, as esti­
mates of statistical significance between different
vs. 60.2% ±  12.1%; MD 6.9 [95% Cl 2.1 % -  1 !.7% |).
There was no correlation between age and specific 
M THFR activity (data not shown).
The prevalence of the homozygous 677C->T mutation
groups Odds ratios and 95% Cl were calculated (Mor- jn the MXHFR c was examined in patients with car-
ris and Gardner 1989) to estimate the relative risk of diovascular disease, as well as in control subjects. In the
the homozygous mutation and of a homocysteine con- tíent u we obsefved an jn d d encc of the homozy-
centration (fasting and post methionine loading) that 
exceeded the 90th percentile of the control group. These 
odds ratios were adjusted for age and gender, by use of
gous transition (-H/+ genotype) in 9 (15%) of 60 cases, 
which is significantly higher than 6 (5.4%) of 1 1 1 con­
trols (table 2 ), The calculated odds ratio for the -1-/H-
a logistic regression model. Correlation analyses were m.n..,vn(, w „, ■> (9 ™  r i  , ()_ 9 2 \
„„fo rm e d  by S .^ n n a n 's  rank ,cS. ( ,.) . T o ^  thc' clIITdi, tk ,„  L ™ ,  and No-
^ esul s^ chemical phenotype, we divided all individuals into three
distinct subgroups based on their MTHFR genotype 
Fasting and post-methion.ine-loading homocysteine (-17-1-, 47—, and - 7 - ) .  Individuals with the 4-/-1- genotype 
concentrations were measured in 58 patients and in 11 1 showed markedly elevated homocysteine, compared with
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Table t





(jimol/liter) 14.1 ±  5.1 (w =  5B) 12.5 ±  4.0 (n = 111)
Post-methione-loading homocysteine1’
(jimol/litcr) 44.5 ±  18.6 (n =  58) 38.6 ±  13.0 (n = 110)
No*!’a — Results are expressed as mean ±  SD. 
11 Moan difference 1,6 (.95% Cl 0 ,2 -3 ,0 ) . 
b Mentt difference 5.9 (95% Cl 1 ,0 -10 ,8 ),
individuals with the - / -  genotype (table 3). A striking et al. 19.92), we found elevated plasma homocysteine
correlation was observed between genotype and specific concentrations in cardiovascular disease patients com-
MTHFR activity or residual MTHFR activity, with only pared with controls* In patients with cardiovascular dis-
a small overlap between the + /+  genotype and the two ease and mildly elevated homocysteine concentrations,
othei* genotypes (fig. 1), Patients and controls with the we (Boers et al, 19856) and others (Clarke et al, 1991)
+/H- genotype showed a mean specific MTHFR activity have reported reduced CBS activities, within the range
of < 50%  of the mean specific MTHFR activity of of obligate heterozygotes for CBS deficiency. In both
the —/ -  group (7.8 ±  4.5 \n = 10] vs. 22/1 ±  6.2 [n studies, the enzymatic CBS analyses were performed in
= 81] nmol CH20/m g protein/h). The percentage of mean one and the same laboratory in Manchester (U.K.). Over
residual M THFR activity in the + /+  group was signifi­
cantly lower than that observed in the + /— and —/ —
groups (24.9% ±  10>6% \n ~  10] vs. 53.6% ±  9.0% [n
the past 2 years, we have been unable to reproduce those 
previous findings and found normal CBS activities in 
cultured fibroblasts of 9 of 10 hyperhomocysteinemic 
53] and 65.4% ±  8.1% \n =  81], respectively; fig. vascular disease patients studied in our own laboratory
1). The mean folic acid, vitamin R'12, and vitamin B6 (Engbersen et al. 1995). To date, we have studied 25 
concentrations did not differ significantly between the vascular disease patients with elevated homocysteine 
three MTHFR genotypes (data not shown). In individuals levels and have found normal CBS activities in 24 (96%) 
with the + /+  genotype, a clear negative correlation was of these patients (PI. J. Blom, G. H. J. Boers, and J, M. F. 
observed between fasting homocysteine and plasma folate Trijhels, unpublished data). Because of the contradiction
(rs =  —.94; P <  .001), contrary to the nonsignificant corre­
lations in individuals with the 4 7 — and genotypes. 
Exclusion of a patient with folate deficiency and the 4 / 4  
ge.no type did not change the significance of this correla­
tion. No correlations were found between fasting homo­
cysteine and vitamin B12 or vitamin B6, for any of the 
three MTHFR genotypes (data not shown).
Discussion
In tine with several previous studies (Boers et al.
1985b;  Brattstrom et al. 1990; Clarice et al. 1991; Kang
between previous studies and our present enzymatic 
findings, we examined this inconsistency by molecular 
genetic studies. Among 15 unrelated Dutch homozy-
Table 3
Relationship between Tasting and Posl-Methionine-Loading Plasma 
Homocysteine Concentrations and MTHFR Genotype
pW. t f m r i  ~i n r r i f  tt|Tnu~<>—n n n w  m i




MTHFR Genotype Distribution among Cardiovascular Disease 
Patients and Control Groups
Cardiovascular Disease
Genotype Patients Controls
-f-l-h 15% (n «  9) 5.4%  (n «  6)
35%  (w = 21) 37,8%  (// = 42)






16.3 ± 8.3 13.4 4.0 12.3 ± 3.6
49.8 ± 20.0 41.9 ± 18.0 38.4 ± I 1.7'
N otk.— Results are expressed as mean ± SD.
1 Mean difference 2.9 (95%  Cl 0 -5 ,8 )  for t / 1 vs, I a n d  *1.0 
(95% Cl 1.5-6.5) for + /+  vs. » /~ .
h Mean difference 7.9 (95%  Cl - 2 . 7 -  18.5) for i / f  vs, »/ ;m<l 
1 1.4 (95% Cl 4 .2 -1 8 .6 )  for + /+  vs. ../ .
L* ti sä 92 for this parameter.
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inactivation, of < 3 7 % , with almost no overlap with the 
two other genotypes.
The mean homocysteine level was elevated in individ­
uals homozygous for the mutation in the MTITFR gene, 
although fasting homocysteine concentrations were 
17,1 (iimol/liter (90th percentile of the control group) 
in 60% of the individuals with the 4 / 4  genotype. Ho­
mocysteine concentrations are obviously determined not 
only by genetic factors but also by environmental pa­
rameters, especially nutritional factors. The homocys­
teine levels of subjects with decreased MTITFR activity 
might be more sensitive to low folate intake than those 
in other individuals. Plasma folate appeared to be 
strongly correlated to fasting homocysteine concentra­
tions only in individuals with the 4 / 4  genotype, in con­
trast with the situation in individuals with the 4 7 -  and 
—/ — genotypes. This indicates that plasma folate is criti­
cal in homocysteine homeostasis in individuals with the 
4 / +  genotype. Variations in dietary folate intake in 
these subjects could therefore lead to a diversity in ho­
mocysteine concentration,
Kang et al. (1988#, 1991) reported an incidence of 
thermolabile M T H FR  of 17% among 212 patients with 
coronary artery disease. In the present study, we demon­
go tes for CBS deficiency, we observed the 833T~>C tran- strate that the homozygous 677C~>T mutation, the cause 
sition in 50%  of the alleles. We did not identify any of thermolabile M THFR, is a risk factor for arterioscie- 
833T~*C mutation in 60 cardiovascular disease patients, rotic disease in general, including peripheral and cere- 
whereas in the controls (n — 111) the normal carrier bral arterial occlusive disease, From our results, an odds 
frequency (~ 0 .5 % ) (Boers et al. 198J&) was observed. ratio of 3,1 could be calculated for the 4 / 4  genotype, 
This finding corroborates our enzymatic data and the indicating that the mutation in the homozygous state 
recent results of Whitehead et al. (1994). They were may be an important risk factor for arteriosclerotic dis- 
unable to detect the 919G->A (G307S) mutation in the ease, comparable to hypercholesterolemia or cigarette 
CBS gene, observed in 70%  of Irish homocystinuric al- smoking (Clarke et al. 1991).
specific MTHFR activity
Figure 1 Residual M T H F R  activity after heat inactivation, ver­
sus specific M T H FR  activity in patients and controls w ith the three 
different genotypes. A plus sign ( + ) denotes individuals with the 
+ /+  genotype; a square (□ ) denotes individuals with the + / — geno­
type; and a triangle (A) denotes individuals with —/ — the genotype.
leles, in a group of 100 Irish patients with premature 
vascular disease. Very recently, Kozich et al. (1995) were 
unable to detect mutations in the CBS cDNA in four
In summary, we have no evidence that heterozygosity 
for CBS deficiency predisposes to premature cardiovas­
cular disease. O n the other hand, we show that a com-
hyperhomocysteinemic patients with peripheral occlu- m en  mutation in the M THFR gene, causing elevated
sive arterial disease. Taken together, all enzymatic and 
molecular genetic studies do not provide any evidence 
that heterozygosity for CBS deficiency is a risk factor 
for cardiovascular disease,
We recently demonstrated that the 677C-+T mutation 
in the M TH FR gene results in a thermolabile enzyme in 
vitro (Frosstet al. 1995). In that study and in the present 
report, a correlation was observed between M THFR 
genotype and specific M TH FR activity in isolated lym­
phocytes, In the present study, low M THFR activities 
were demonstrated in subjects with the 4 / 4  genotype; 
intermediate activities occurred in the 4 / — genotype, 
while the highest M TH FR activities were observed in 
subjects with the —/ — genotype. The genotype-pheno- 
type correlation was even more striking when the resid­
ual M T H FR  activity after heat inactivation was exam­
ined for the three genotypes. All subjects with the 4 / 4  
genotype showed a residual M TH FR activity, after heat
homocysteine levels, is a genetic risk factor for prema­
ture cardiovascular disease.
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